Advertisement

Picture Swiss Biotech Association LSE Swiss Biotech Days 2025 Basel 650x100px
Organisation › Details

Tacalyx GmbH

Tacalyx is a privately held biotech company focused on the discovery and development of Tumor Associated Carbohydrate Antigen (TACA) antibodies to treat cancer. TACAs are formed during malignant transformation in a microevolutionary process. The expression of TACAs is elevated in many cancer cell types which makes them attractive potential targets for cancer treatment by harnessing and directing the natural immune response. Tacalyx is developing its proprietary technology platform to exploit TACAs as novel targets for antibody-based therapies, including antibody-drug conjugates (ADCs) and other modalities, and has established a proprietary pipeline with seven independent projects. Tacalyx was founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany, based on work of Prof. Dr. Peter Seeberger and Dr. Oren Moscovitz. Tacalyx is headquartered in Berlin, Germany and is backed by leading European life sciences and technology investors Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners, High-Tech Gründerfonds (HTGF), coparion, Eurazeo/Idinvest Partners, Creathor Ventures, and Thuja Capital. *

 

Period Start 2019-07-04 established (s-off)
  Predecessor Max Planck Institute of Colloids and Interfaces (Potsdam-Golm)
Products Industry TACA antibody
  Industry 2 plaQorm discovery platform
Persons Person Sondermann, Peter (Tacalyx 201909 CEO before Shire + Baxalta + SuppreMol + Roche + Glycart Biotechnology)
  Person 2 Seeberger, Peter H. (MPI of Colloids and Interfaces 2009– Director before ETH Zurich Prof before MIT Prof)
     
Region Region Berlin
  Country Germany
  Street 11 Magnusstr.
3th Floor
  City 12489 Berlin
  Tel +49-30-407237-10
    Address record changed: 2023-11-11
     
Basic data Employees n. a.
     
    * Document for »About Section«: Tacalyx GmbH. (6/11/24). "Press Release: Tacalyx Extends Seed Round to over €14 M to Advance Development of its Cancer Therapeutics Targeting TACAs". Berlin.
     
   
Record changed: 2024-12-29

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x200px

More documents for Tacalyx GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Events RegMed Forum 2025 HealthCapital 650x300px




» top